Internal Medicine

Dr. Juliana Biondo discusses what the future of treatment for hemophilia A looks like based on ongoing trials.

The American Indian and Alaska Native population show the largest increase in median state ratios, rising from 14 - 49.2, while the Black population consistently had the highest median state ratios, increasing from 26.7 - 55.4.

Dr. Juliana Biondo discusses the exciting FDA approval of Roctavian and how it compares with other treatment options like Hemlibra.

While the FDA decision of Roctavian offers patients with hemophilia A more options, the gene therapy eligibility criteria still pose barriers.

Despite concerns, Dr. Margaret Ragni discusses the significance of the Roctavian's effectiveness for reducing hemophilia A bleeds and improving patient quality of life.

The data provide promising results, yielding a smoking abstinence rate of 26.4% in the intervention group at 18 months.

The approval is supported by positive results from the largest and longest phase 3 study for gene therapy in hemophilia, showing a 52% reduction in annualized bleeding rate compared with baseline rates on routine prophylaxis.

A new study highlights the benefits of using the hypertonic saline test to determine the appropriate dose of inhaled corticosteroids for managing asthma in children.

Significant improvements seen in hematologic parameters, visceral volumes, and plasma biomarkers in patients with Gaucher disease, suggesting its potential as an alternative therapy, particularly for those who cannot access enzyme replacement therapy.

Ritlecitinib becomes the second JAK inhibitor approved to treat alopecia—and the first to be indicated for patients aged 12 years and older.

Communities already facing social vulnerabilities are more likely to bear the burden of increased smoke exposure.

Findings show patients hospitalized for COVID-19 have an increased 1-year risk of venous thromboembolic disease compared with those hospitalized for influenza (HR, 1.77; 95% CI, 1.36-2.31).

Among other associations, those in educational attainment, employment status, mental health, and pain episode frequency and severity highlight the need for comprehensive care that considers the psychological well-being of individuals with SCD.

Investigators explain understanding these disparities is crucial for developing targeted interventions to improve screening rates and reduce health inequities.

Criner and colleagues concluded that the 5-year results from the EMPROVE trial demonstrated that Spiration Valve System (SVS) treatment was safe and durable, effectively improving lung function in patients with emphysema

Diagnosis, evaluation, and treatment recommendations for pregnant individuals with asthma follow similar principles as for nonpregnant patients, but investigators address specific challenges.

New prognostic model enhances methotrexate monitoring for immune-mediated inflammatory diseases.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Patients treated with NAL ER demonstrated a 75.1% decrease in daytime cough frequency and a 76.1% decrease in 24-hour cough frequency compared with placebo.

Celularity's clinical trial of CYNK-001 for relapsed and refractory AML showed excellent tolerability, significant graft-versus-leukemia effects, and potential for flexible therapeutic development.

An analysis of over 300,000 Medicare admissions showed no clinically important differences regarding mortality, readmission, length of stay, and healthcare spending between the two groups.